P
Peter G. Steinherz
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 187
Citations - 12713
Peter G. Steinherz is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Acute lymphocytic leukemia & Leukemia. The author has an hindex of 55, co-authored 186 publications receiving 11984 citations. Previous affiliations of Peter G. Steinherz include University of Chicago & Children's Oncology Group.
Papers
More filters
Journal ArticleDOI
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens,Marco L. Davila,Isabelle Riviere,Jae H. Park,Xiuyan Wang,Lindsay G. Cowell,Shirley Bartido,Jolanta Stefanski,Clare Taylor,Malgorzata Olszewska,Oriana Borquez-Ojeda,Jinrong Qu,Teresa Wasielewska,Qing He,Yvette Bernal,Ivelise Rijo,Cyrus V. Hedvat,Rachel Kobos,Kevin J. Curran,Peter G. Steinherz,Joseph G. Jurcic,Todd L. Rosenblat,Peter Maslak,Mark G. Frattini,Michel Sadelain +24 more
TL;DR: The results demonstrate the marked antitumor efficacy of 19-28z CAR-modified T cells in patients with relapsed/refractory B-ALL and the reliability of this therapy to induce profound molecular remissions, forming a highly effective bridge to potentially curative therapy with subsequent allo-HSCT.
Journal ArticleDOI
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
TL;DR: The 23% incidence of late cardiac abnormalities warrants continued evaluation of patients after anthracyclines to guide patient care and the design of future chemotherapeutic protocols.
Journal ArticleDOI
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Steven L. Soignet,Stanley R. Frankel,Dan Douer,Martin S. Tallman,Hagop Kantarjian,Elizabeth Calleja,Richard Stone,Matt Kalaycio,David A. Scheinberg,Peter G. Steinherz,Eric L. Sievers,Steven Coutre,Steve Dahlberg,Ralph Ellison,Raymond P. Warrell +14 more
TL;DR: This study establishes ATO as a highly effective therapy for patients with relapsed APL as well as establishing its use as a maintenance therapy.
Journal ArticleDOI
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.
Brian H. Kushner,Michael P. LaQuaglia,Norma Wollner,P. A. Meyers,Karen L. Lindsley,F. Ghavimi,Thomas E. Merchant,Farid Boulad,Nai-Kong V. Cheung,Mary Ann Bonilla,G. Crouch,J. F. Kelleher,Peter G. Steinherz,William L. Gerald +13 more
TL;DR: For control of DSRCT, the experience supports intensive use of HD-CAV, aggressive surgery to resect visible disease, radiotherapy to high-risk sites, and myeloablative chemotherapy with stem-cell rescue in selected cases.
Journal ArticleDOI
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
Sima Jeha,Bassem I. Razzouk,Michael Rytting,Susan R. Rheingold,Edythe Albano,Richard Kadota,Lori Luchtman-Jones,Lisa Bomgaars,Paul S. Gaynon,Stewart Goldman,Kim Ritchey,Robert J. Arceci,Arnold J. Altman,Kimo C. Stine,Laurel J. Steinherz,Peter G. Steinherz +15 more
TL;DR: Clofarabine is active as a single agent in pediatric patients with multiple relapsed or refractory ALL and the toxicity profile is as expected in this heavily pretreated patient population.